Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr Kitko on the Utility of Obe-Cel in Pediatric Patients With B-ALL

May 23rd 2024

Carrie L. Kitko, MD, discusses the use of obecabtagene autoleucel for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr Leslie on the Utility of Axi-cel in High-Risk LBCL

May 22nd 2024

Lori A. Leslie, MD, discusses the utility of treatment with axi-cel through the lens of the ZUMA-7 trial in large B-cell lymphoma.

Eckfeldt Looks Towards the Future of AML and MDS Care

May 22nd 2024

Craig Eckfeldt, MD, PhD, discusses key updates in the MDS treatment paradigm and the implications of MRD testing, as well as next steps in the field of AML.

CAR T-Cell Therapies Move Ahead in Pediatric and Adult ALL

May 22nd 2024

Carrie L. Kitko, MD, discusses the current standing of cellular therapies in adult and pediatric ALL and looks toward future developments.

Neelapu Highlights the Nuances of CAR T-Cell Therapy Administration in Lymphoma

May 20th 2024

Sattva S. Neelapu, MD, discusses the optimal processes of CAR T-cell therapy administration and the remaining unmet needs in the space.

WU-CART-007 Receives FDA RMAT and EMA PRIME Designations for R/R T-ALL and T-LBL

May 20th 2024

WU-CART-007 has received RMAT and PRIME designations in relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

CAR T-Cell Agents Offer Efficacy in Lymphoma, But Additional Approaches Are Needed to Overcome Resistance

May 17th 2024

Sattva S. Neelapu, MD, discusses the current standing of CAR T-cell therapies in the treatment paradigm in lymphoma.

FDA Grants Accelerated Approval to Liso-Cel for Relapsed/Refractory Follicular Lymphoma

May 15th 2024

The FDA has granted accelerated approval to lisocabtagene maraleucel for the treatment of select adult patients with relapsed or refractory follicular lymphoma.

Dr Leslie on the Management of CAR T-Cell Therapy Toxicities in LBCL

May 14th 2024

Lori A. Leslie, MD, discusses the evolution in managing toxicities associated with CAR T-cell therapy in patients with LBCL.

Dr Deng on the Evolution of the Hodgkin Lymphoma Treatment Paradigm

May 13th 2024

Changchun Deng, MD, PhD, discusses the evolution of Hodgkin lymphoma management following data readouts at the 2023 ASH Annual Meeting.

Revisit Every OncLive On Air Episode From April 2024

May 13th 2024

In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.

Ongoing Research Aims to Expand Treatment Options, Address Unmet Needs in GVHD

May 12th 2024

Mohamad Mohty, MD, PhD, discusses unmet needs for patients with chronic or acute GVHD, for whom standard-of-care therapies often fall short.

Dr Koehne on the Use of Chemotherapy-Only Conditioning Regimens in Hematologic Malignancies

May 8th 2024

Guenther Koehne, MD, PhD, discusses the use of chemotherapy-only conditioning regimens for patients with hematologic malignancies undergoing transplant.

Loncastuximab Tesirine Elicits Responses in R/R Marginal Zone Lymphoma

May 7th 2024

Treatment with loncastuximab tesirine yielded high response rates in patients with relapsed or refractory marginal zone lymphoma.

Dr Aldoss on the Utility of Ponatinib in Ph+ ALL

May 6th 2024

Ibrahim Aldoss, MD, discusses the utility of ponatinib in the phase 3 PhALLCON trial for patients with newly diagnosed, Ph+ acute lymphoblastic leukemia.

Uproleselan Plus Chemotherapy Misses OS End Point in R/R AML

May 6th 2024

Uproleselan plus chemotherapy did not achieve a statistically significant improvement in OS vs chemotherapy alone in patients with relapsed/refractory AML.

AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle Forward

May 6th 2024

Leland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.

Which JAK Inhibitor in Myelofibrosis: Deciding Factors in Treatment Selection

May 3rd 2024

Rebecca Klisovic, MD, discusses 4 case studies of patients who presented with varying types of myelofibrosis and the appropriate treatment avenues for each patient.

Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma

May 2nd 2024

Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.

Dr Jallouk on Preventing Post-Transplant Relapse in R/R Hematologic Malignancies

May 2nd 2024

Andrew P. Jallouk, BS, MD, PhD, discusses research assessing post-transplant relapse prevention strategies in patients with hematologic malignancies.